NCT06379217
NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 33 versions: 27 with changes below, 6 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Stopped Trial terminated Sponsor's reason: Sponsor decision and not a consequence of any safety concerns.
- Primary completion date changed from estimate of Sep 11, 2026 to Oct 16, 2026
- Secondary endpoints: 18 to 16
- Study description shortened, about 1 word
- Minor Primary and study completion dates: Sep 11, 2026 to Oct 9, 2026
Notable Eligibility criteria expanded, about 17 words Show 5 more changesShow less
- Primary endpoints: details revised at 1 of 2 entries
- Primary and study completion dates: Aug 31, 2026 to Sep 11, 2026
- Interventions: Antiemetics & antinauseants (Drug), GnRH antagonists (Drug), Gonadotropin-releasing hormone (GnRH) analogues (Drug), L-Lysine… to Antiemetics & antinauseants (Drug), GnRH antagonists (Drug), Gonadotropin-releasing hormone (GnRH) analogues (Drug), L-Lysine…
- Secondary endpoints: details revised at 13 of 18 entries
- Study description revised
- Minor Primary and study completion dates: Aug 24, 2026 to Aug 31, 2026v29
- Minor Study sites: 11 to 9v26
Show 21 earlier versionsHide 21 earlier versions
- Minor Primary and study completion dates: Aug 27, 2026 to Aug 24, 2026
- Study description expanded, about 11 words
- Minor Enrollment target: 28 to 31
- Primary and study completion dates: Jun 23, 2027 to Aug 27, 2026
- Minor Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 36 to confirmed 28
- Study sites: 14 to 11
- Minor Site details revised at 8 of 14 sitesv22
- Notable Eligibility criteria expanded, about 3 words
- Study sites: 12 to 14
- Primary and study completion dates: Jun 22, 2027 to Jun 23, 2027
- Study description expanded, about 35 words
- Minor Site contacts updated at 2 of 12 sitesv20
- Minor Study sites: 11 to 12v19
- Minor Study sites: 9 to 11v18
- Minor Study sites: 8 to 9v17
- Minor Site contacts updated at 1 of 8 sitesv16
- Minor Site contacts updated at 1 of 8 sitesv15
- Minor Site contacts updated at 1 of 8 sitesv14
- Minor Study sites: 7 to 8v13
- Minor Study sites: 4 to 7v12
- Minor Site contacts updated at 1 of 4 sitesv11
- Minor Study sites: 3 to 4
- Secondary endpoints: details revised at 1 of 18 entries
- Notable Primary endpoints revised (2)v7
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 3
- Start date changed from estimate of Aug 31, 2024 to Jul 29, 2024
- Notable Start date: Jul 31, 2024 to Aug 31, 2024v5
- Notable Start date: Jun 18, 2024 to Jul 31, 2024v4
- Minor Primary and study completion dates: Jun 4, 2027 to Jun 22, 2027v3
- Study First Submitted
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Number/extent of lesions with at least a moderate uptake of any of the Radioligand Imaging (RLI)
Timeframe: Baseline (baseline imaging is performed during the 42 day screening period)
Percentage changes in quantitative PET parameters.
Timeframe: Post-Baseline (from date of baseline imaging scans to post-baseline scans, at least 6 weeks after receiving the first cycle of radioligand treatment)
Secondary (16)
Overall Response Rate (ORR)
Disease Control Rate (DCR)
Duration of response (DOR)
Radiographic Progression-free Survival (rPFS)
Proportion of participants with a decline in PSA level
Show 11 moreShow less
Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) for Radioligand Therapy (RLT)
Dose modifications for [177Lu]Lu-PSMA-617, [177Lu]Lu-DOTA-TATE and [177Lu]Lu-NeoB
Dose intensity for [177Lu]Lu-PSMA-617, [177Lu]Lu-DOTA-TATE and [177Lu]Lu-NeoB
Duration of exposure for [177Lu]Lu-PSMA-617, [177Lu]Lu-DOTA-TATE and [177Lu]Lu-NeoB
Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) for Radioligand Imaging (RLI)
Blood radioactivity concentration of [177Lu]Lu-PSMA-617, [177Lu]Lu-DOTA-TATE, [177Lu]Lu-NeoB)
Observed maximum blood concentrations (Cmax) of [177Lu]Lu-PSMA-617, [177Lu]Lu-DOTA-TATE and [177Lu]Lu-NeoB
Time of maximum blood concentration (Tmax) occurence of [177Lu]Lu-PSMA-617, [177Lu]Lu-DOTA-TATE and [177Lu]Lu-NeoB
Area under the blood concentration time curve (AUC) of [177Lu]Lu-PSMA-617, [177Lu]Lu-DOTA-TATE and [177Lu]Lu-NeoB
Absorbed radiation doses of [177Lu]Lu-PSMA-617, [177Lu]Lu-DOTA-TATE and [177Lu]Lu-NeoB
Time Activity Curves (TACs) of [177Lu]Lu-PSMA-617, [177Lu]Lu-DOTA-TATE and [177Lu]Lu-NeoB
Arms and interventions
PSMA-predominant Neuroendocrine prostate cancer (NEPC)Experimental
Somatostatin Receptor 2 (SSTR2)-predominant NEPCExperimental
Gastrin Releasing Peptide Receptor (GRPR)-predominant NEPCExperimental
Drugs: [68Ga]Ga-PSMA-11, [68Ga]GA-DOTA-TATE, [68Ga]Ga-NeoB, [177Lu]Lu-PSMA-617, [177Lu]Lu-DOTA-TATE, [177Lu]Lu-NeoB, L-Lysine HCl-L-Arginine HCl, 2.5 %,, Gonadotropin-releasing hormone (GnRH) analogues, GnRH antagonists, Antiemetics & antinauseants, Metoclopramide
Sites
9 sites in 5 countries
Germany 2, Spain 2, United Kingdom 2, United States 2, France 1